About
FluoretiQ Limited is a UK-based biomedical startup and medical device company founded in 2017. The company specializes in rapid bacterial identification and diagnostics using advanced glycan chemistry and fluorescence sensor technology. FluoretiQ aims to enhance antibiotic stewardship by providing fast, accurate, point-of-care diagnostic tools, ensuring that the first prescription is the right one. The company develops a range of diagnostic tools for veterinary and clinical use. Its flagship technology platform, NANOPLEX®, features an advanced latex agglutination test that can identify and quantify bacteria in just 15 minutes. The first product launched using this technology is VERI-5 VET, designed for veterinary diagnostics. Additionally, FluoretiQ offers the SCFI™ platform, a real-time antibiotic susceptibility test that determines the most effective antibiotic within 30 minutes. FluoretiQ's technology significantly reduces diagnostic times, improving patient outcomes and reducing healthcare costs. The company collaborates with organizations like Cancer Research UK and Innovate UK to expand its applications, serving a customer base that includes veterinarians and clinicians.
Technologies
Keywords
Company Information
-
Employees 13
-
Founded 2017
-
Annual Revenue $1000000
-
Total Funding $1493877
Location
Albert Road, Bristol, England, United Kingdom, BS2 0